Skip to main content

Axitinib News

Sustained Clinical Benefit Seen for Pembrolizumab + Axitinib in Advanced Renal Cancer

FRIDAY, Aug. 8, 2025 – For patients with advanced renal cell carcinoma (RCC), there is a sustained clinical benefit with pembrolizumab plus axitinib, according to a study published online Aug. 6 in...

FDA Approves Bavencio (avelumab) Plus Inlyta (axitinib) Combination for Patients with Advanced Renal Cell Carcinoma

Darmstadt, Germany and New York, US, May 14, 2019 – Merck KGaA, Darmstadt, Germany, which operates its biopharmaceutical business as EMD Serono in the US and Canada, and Pfizer Inc. (NYSE: PFE) today ...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Renal Cell Carcinoma

Axitinib patient information at Drugs.com